HIV is Still Growing, Even When Undetectable in the Blood
Study challenges previous beliefs about dormant virus and charts a “path to a cure”
- New avenues revealed for more effective HIV treatment
- Hidden virus found growing in protected drug sanctuaries
- Novel deep sequencing technique reveals HIV moving through body in time and space
- Drugs need to penetrate sanctuaries in lymphoid tissue to cure HIV
CHICAGO --- A team of international scientists led by Northwestern University found that HIV is still replicating in lymphoid tissue, even when it is undetectable in the blood of patients on antiretroviral drugs.
The findings provide a critical new perspective on how HIV persists in the body despite potent antiretroviral therapy.
“We now have a path to a cure,” said corresponding author Dr. Steven Wolinsky, chief of infectious diseases at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. “The challenge is to deliver drugs at clinically effective concentrations to where the virus continues to replicate within the patient.”
The paper was published January 27 in the journal Nature.
Combinations of potent antiretroviral drugs quickly suppress HIV to undetectable levels in the bloodstream of most patients, but HIV persists in a viral reservoir within lymphoid tissue in the body. The virus rapidly rebounds in the blood if patients stop their drugs. This suggests that long-lived latently infected cells and/or ongoing low levels of HIV replication maintain these viral reservoirs.
Up until now, most scientists believed the reservoir only contained long-lived infected cells in a resting state rather than newly infected cells for several reasons. First, no one had seen viruses with the new genetic mutations that inevitably arise when HIV completes cycles of growth. Second, most patients do not develop the drug resistance mutations which might seem likely, if HIV was growing in the presence of drugs.
The team examined viral sequences in serial samples of cells from lymph nodes and blood from three HIV-infected patients from the University of Minnesota (U of M) who had no detectable virus in their blood. Scientists found that the viral reservoir was, in fact, constantly replenished by low-level virus replication in lymphoid tissue with infected cells then moving from these protected sanctuaries into the blood.
Because infected cells in drug-sanctuaries within lymphoid tissue can still produce new viruses, infect new target cells and replenish the viral reservoir, it has not been possible to purge the body of latently infected cells and eradicate the virus.
A mathematical model tracked the amount of virus and the number of infected cells as they grew and evolved in drug sanctuaries, then moved through the body. The model explains how HIV can grow in drug sanctuaries in lymphoid tissue where antiretroviral drug concentrations are lower than in the blood, and why viruses with mutations that create high-level drug-resistance do not necessarily emerge.
The findings provide a new perspective on how HIV persists in the body despite potent antiretroviral therapy. The study also explains why the development of drug resistance is not inevitable when virus growth occurs in a place where drug concentrations are very low.
Most importantly, this new understanding highlights how important it is to deliver high concentrations of antiretroviral drugs to all locations in the body where HIV can grow. Drugs that penetrate the newly discovered sanctuaries will be a prerequisite to the elimination of the viral reservoir and, ultimately, a step towards a cure.
“The study is exciting because it really changes how we think about what is happening in treated patients,” said co-author Angela McLean, professor of mathematical biology at Oxford University, who supervised the mathematical modelling. “It helps explain why some strategies that tried to clear the reservoir have failed.”
Other authors on the paper include Ramon Lorenzo-Redondo, Eun-Young Kim and Sudhir Penugonda of Northwestern University; Helen R. Fryer of the University of Oxford, Oxford, UK; Jeffrey Chipman, Timothy W. Schacker and Ashley T. Haase of the U of M, Minneapolis; Trevor Bedford of the Fred Hutchinson Cancer Research Center, Seattle; Sergei L. Kosakovsky Pond of Temple University, Philadelphia; Yoon-Seok Chung of the Korean National Institutes of Health, Korea; Courtney V. Fletcher of the University of Nebraska Medical Center, Omaha; Michael H. Malim of King's College London; Andrew Rambaut of the University of Edinburgh, Edinburgh, UK; and John Archer of Centro de Investigação em Biodiversidade e Recursos Genéticos Universidade do Porto in Portugal.
The study was supported in part by grants DA033773, AI1074340 and GM110749 from the National Institutes of Health, grant G1000196 by the Medical Research Council, grant 278433-PREDEMICS by the Framework Programme for Research and Technological Development, grant 260864 by the European Research Council, the Oxford Martin School, All Souls College and the Royal Society.